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Peroxisomeproliferator-activatedreceptors(PPARs)belongtothenuclearreceptorfamilyofligand-activatedtranscriptionfactors.
This subfamily is composed of three members—PPARα,P P A R δ,a n dP P A R γ—that diﬀer in their cell and tissue distribution as
well as in their target genes. PPARα is abundantly expressed in liver, brown adipose tissue, kidney, intestine, heart, and skeletal
muscle; and its ligands have been used to treat diseases such as obesity and diabetes. The recent ﬁnding that members of the
PPAR family, including the PPARα, are expressed by tumor and endothelial cells together with the observation that PPAR ligands
regulate cell growth, survival, migration, and invasion, suggested that PPARs also play a role in cancer. In this review, we focus on
the contribution of PPARα to tumor and endothelial cell functions and provide compelling evidence that PPARα can be viewed
as a new class of ligand activated tumor “suppressor” gene with antiangiogenic and antitumorigenic activities. Given that PPAR
ligands are currently used in medicine as hypolipidemic drugs with excellent tolerance and limited toxicity, PPARα activation
might oﬀer a novel and potentially low-toxic approach for the treatment of tumor-associated angiogenesis and cancer.
Copyright © 2008 A. Pozzi and Jorge H. Capdevila. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. THE PEROXISOMAL PROLIFERATOR-ACTIVATED
RECEPTORS (PPARs)
PPARs nuclear receptors that regulate many physiological
processes, including lipid and glucose homeostasis, inﬂam-
mation, and wound healing [1]. Three PPAR isotypes have
been identiﬁed: α, δ (or β), and γ. Upon ligand binding,
PPARs form heterodimers with the retinoic acid receptor
and interact with speciﬁc response elements in the promoter
region of target genes [2]. Although PPARs share extensive
structural homology, each isotype appears to possess distinct
functions.PPARγ isexpressedmainlyinadiposetissueandat
lower levels in intestine and immune cells [3–5]. It controls
adipocyte diﬀerentiation, glucose and lipid homeostasis [5–
7] and has been implicated in the pathophysiology of
insulin resistance and atherosclerosis [1, 8]. PPARγ ligands
include long-chain fatty acids, prostaglandins, and other
eicosanoids [4]. Among the synthetic PPARγ ligands, the
thiazolidinediones are currently used as insulin sensitizers
in patients with type-2 diabetes [9]. PPARδ is ubiquitously
expressed and it is most abundant in brain, colon, and
skin [10, 11], and binds molecules such as fatty acids and
prostaglandins [4].
PPARα is primarily expressed in liver, brown adipose
tissue, kidney, intestine, heart, and skeletal muscle. This
receptor controls fatty acid metabolism and transport, per-
oxisomal and mitochondrial β-oxidation [3, 4]. Moreover,
this receptor has been implicated in the pathophysiology
of inﬂammation and cardiovascular diseases [12]. Several
compounds bind PPARα, including fatty and phytanic acids
[4], as well as the ﬁbric acid derivatives used in medicine for
the treatment of hyperlipidemias [1].
2. PPARs AND CANCER
The observation that members of the PPAR family are
expressed by tumor and endothelial cells [13, 14] together
with the ﬁnding that PPAR ligands regulate cell growth,
survival, migration, and invasion [15, 16]p r o m p t e di n v e s t i -
gators to determine whether these receptors play a role in the
pathophysiology of tumorigenesis and angiogenesis [17, 18].
The anticancer eﬀects of PPARγ agonists have been
extensively studied because of their antiproliferative, proap-
optotic, antiapoptotic, and diﬀerentiation-promoting activ-
ities [19]. In this context, activation of PPARγ has been2 PPAR Research
reported to reduce tumor cell proliferation and invasion [20]
and to enhance apoptosis [21]. PPARγ ligands also regulate
endothelial cell growth, migration, and angiogenesis [22–
25], and inﬂuence the progression of vascular inﬂammation
and tumorigenesis [26, 27]. Moreover, disruption of the
PPARγ gene in the intestine enhances tumorigenesis in
ApcMin/+ mice [28]. Although these studies suggest that
PPARγ functions as a tumor suppressor factor and its
activation might be beneﬁcial for patients with tumors,
PPARγ agonists have been shown also to increase the
frequency of colon tumors [29] and to promote edema [30].
In contrast to PPARγ,P P A R δ has been described as
protumorigenic as its ligand-mediated activation increases
tumor-associated angiogenesis [31]. Moreover, treatment of
ApcMin/+ mice with PPARδ antagonists or crossing these
mice with PPARδ-null mice prevents tumor growth and
angiogenesis [31]. However, a recent study showed that
activation of this receptor attenuates chemically-induced
colon carcinogenesis, and that PPARδ-null mice exhibit
increased colon polyp multiplicity, suggesting that ligand
activation of this receptor can also inhibit carcinogenesis
[32].
The analysis of the antitumorigenic properties of PPARα
ligands has been less studied mostly due to the observation
that long-term administration of certain PPARα agonists
(Cloﬁbrateand WY14643) induces hepatocarcinogenesis in
rodents [33–35], despite the fact that PPARα ligands are
widelyusedinmedicineasantilipidemicdrugswithexcellent
tolerance and little or no reported side eﬀects. The ﬁnding
that fenoﬁbrate decreases VEGF levels in patients with
hyperlipidemiaand atherosclerosis [36]p r o v i d e dar a t i o n a l e
for analyzing PPARα and its ligands as a molecular target for
cancer therapy. In this review, we highlight some of the key
functions attributed to PPARα in the context of endothelial
and tumor cell biology.
3. PPARα TARGETS IN ANGIOGENESIS
PPARα controls the transcription of many genes involved in
cell functions such as lipid metabolisms, inﬂammation, cell
cycle progression, and angiogenesis. Among the angiogenic
targets, PPARα has been shown to regulate the expression
of the vascular endothelial growth factor (VEGF), ﬁbroblast
growth factors (FGFs), members of the arachidonic acid
P450 monooxygenases, thrombospondin and endostatin to
name few (see also Figure 1 and Table 1). Biscetti et al. have
recently shown that the selective PPARα agonist WY14643
promotescorneaangiogenesisinvivoandenhancesendothe-
lial tubulogenesis in vitro [37]. Interestingly, WY14643 can
enhance endothelial cell tubulogenesis in vitro only when
endothelial cells are cocultured with interstitial cells and this
eﬀect is accompanied by upregulation of interstitial-derived
VEGF synthesis [37]. However, WY14643 does not directly
promote endothelial cell migration or proliferation, and
when used at 10–20μM range it reduces both endothelial cell
proliferation and migration [37]. Thus, this study indicates
that while WY14643 might directly prevent endothelial cell
functions, it might also promote angiogenesis by stimulating
the production of nonendothelial VEGF. The observation
that activation of PPARα prevents endothelial cell pro-
liferation/migration parallels our ﬁndings that WY14643
prevents—in a PPARα-dependent fashion—endothelial cell
proliferation in vitro and tumorigenesis in vivo [38].
The antiangiogenic properties of WY14643 are associated
with a PPARα-dependent downregulation of the epoxy-
genase branch of the cytochrome P450 arachidonic acid
monooxygenases [38]. The arachidonic acid epoxygenases
are expressed by endothelial cells both in vitro and in vivo
[39–41] and catalyze the oxidation of arachidonic acid to
four regioisomeric epoxyeicosatrienoic acids (EETs) [42, 43].
EETs have been shown to possess proangiogenic activities
[39, 44–47] and we have demonstrated that WY14643-
mediated PPARα activation directly prevents endothelial cell
migration and proliferation by downregulating endothelial
arachidonate epoxygenase expression and EET biosynthesis
[38]. Most importantly, in vivo treatment with WY14643
prevents primary tumor growth and tumor-associated
angiogenesisbydownregulatingthelevelsofcirculatingEETs
[38].
Consistent with the observation that PPARα ligands
might act as potent direct and/or indirect antiangiogenic
factors, Panigrahy et al. have recently shown that fenoﬁbrate
suppresses VEGF-mediated endothelial cell proliferation as
well as tumor cell-derived VEGF and FGF2 synthesis with
concomitant stimulation of tumor-cells derived throm-
bospondin and endostatin [48]. Moreover, fenoﬁbrate and
WY14643 prevent VEGF-mediated endothelial cell migra-
tion by inhibiting Akt phosphorylation [24] and fenoﬁ-
brate prevents endothelial cell proliferation by inhibiting
cyclooxygenase-2 expression [25]. Finally, PPARα agonists
were found to inhibit endothelial VEGFR2 expression by
preventing Sp1-dependent promoter binding and transac-
tivation [23]. Some of the major PPARα targets known to
control endothelial cell functions and the eﬀects of PPARα
ligands on angiogenesis are summarized in Figure 1 and
Table 1.
In conclusion these studies strongly suggest that by pre-
ventingendothelialcellfunctionsPPARαligandsmayprotect
the vasculature from pathological alterations associated with
either metabolic disorders (i.e., atherosclerosis, diabetes)
or cancer. Thus, PPARα can be considered as a new class
of “antiangiogenic” gene, and suggest that its ligands may
function as eﬀective antiangiogenic drugs.
4. PPARα TARGETS IN CANCER
The observation that PPARα is expressed by tumor cells
[59–61] started studies of the role of this nuclear receptor
and its ligands on the prevention of tumor cell proliferation
in vitro and in vivo. In this context it has been shown
that PPARα ligands suppress the growth of several can-
cer lines—including colon, liver, breast, endometrial, and
skin—in vitro [62–66], as we all inhibit the metastatic
potential of melanoma cells in vitro and in vivo [67, 68].
Furthermore, PPARα ligands decrease colon carcinogenesis
[62] and the growth of human ovarian cancer in mice
[49]. Although the mechanisms whereby PPARα directly
prevents tumor cell functions have not been investigatedA. Pozzi and Jorge H. Capdevila 3
Table 1: Eﬀect of PPARα activation on angiogenesis and tumorigenesis.












t u b ef o r m a t i o ni nv i t r o
Proangiogenic activity in
vivo















WY14643 Endothelial cells Reduced cell migration Inhibition of Akt activation [24]





Fenoﬁbrate Endothelial cells Reduced cell







Reduced prostanoid and VEGF levels






proliferation Not investigated [50]
Methylclofenapate Apc
Min/+ mice Reduced number of






Reduced serum level of triglycerides







Downregulation of the miRNA














VEGF- or FGF2-mediated proliferation and migration
Direct PPARα ligand-mediated anti-angiogenic functions
Direct PPARα ligand-mediated anti-tumorigenic functions
Indirect PPARα ligand-mediated anti-angiogenic functions
Figure 1: Schematic representation of the antiangiogenic and antitumorigenic properties of PPARα.P P A R α ligands reduce tumor growth by
direct inhibition of tumor cell functions (black pathway). In addition, they prevent tumor-associated angiogenesis via direct (red pathway)
as well as indirect (green pathway) inhibition of endothelial cell functions.4 PPAR Research
Table 2: PPARα and tumorigenesis: lessons from the PPARα-null mice.
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in details, potential targets have been identiﬁed. Cloﬁbrate,
aP P A R α ligand, signiﬁcantly suppressed the growth of
OVCAR-3 xenotransplanted tumors and inhibited ovarian
tumor cell proliferation by increasing the expression of
carbonyl reductase, an enzyme that promotes the conversion
of protumorigenic prostaglandin E2 to inactive PGF2α [49].
Moreover, cloﬁbrate reduced the levels of circulating VEGF
in tumor-bearing mice [49], while bezaﬁbrate, another
PPARα ligand, decreased the number of intestinal polyps
in ApcMin/+ mice possibly by lowering serum level of
triglycerides and upregulating lipoprotein lipase synthesis
[27, 51]. Finally, PPARα activation has been shown to
inhibit vascular smooth muscle cell proliferation underlying
intimal hyperplasia by inducing the expression of the tumor
suppressor p16INK4a [56].
Whereas these studies clearly suggest that PPARα activa-
tion might be beneﬁcial in reducing cancer growth, studies
from the Gonzales laboratory demonstrate that long-term
administration of certain PPARα agonists (cloﬁbrate and
WY14643) induces liver adenoma and carcinomas in rats
and mice [35, 52, 69, 70]. The ability of PPARα ligands to
induce hepatocarcinoma is PPARα-dependent and mediated
by the novel microRNA let-7C/c-myc axis [52]. Let-7C is
a micro RNA that controls cell growth by directly down-
regulating c-myc expression [52]. Upon treatment of mice
with WY14643, the hepatic expression of let-7C decreases
with the concomitant induction of c-myc and the increased
expression of the oncogenic mir-17-92 cluster [52]. Thus,
this novel rodent speciﬁc PPARα-regulated pathway might
be responsible for increased hepatocellular proliferation and
tumorigenesis.
All together, these ﬁndings indicate that, with few
exceptions, PPARα ligands can be viewed as antitumorigenic
agents either by directly preventing tumor cell functions or
by preventing tumor-derived production of proangiogenic
molecules. Some of the potential PPARα targets that control
tumor cell functions and the eﬀects of PPARα ligands on
tumorigenesis are summarized in Figure 1 and Table 1.
5. PPARα LIGANDS AND TUMORIGENESIS:
LESSONS FROM MICE
ThegenerationofPPARαnullmicehasprovidedanexcellent
tool not only to determine whether the eﬀects exerted
by PPARα ligand are indeed PPARα-dependent, but also
for discerning between host versus tumor-mediated PPARα
responses (see Table 2 for details). In this regard, we have
shown that wild-type mice injected with isogenic PPARα
expressing tumor cells respond to WY14643 treatment and
develop fewer and smaller tumors than untreated wild-type
mice [38]. In contrast, the growth of the same tumor cells isA. Pozzi and Jorge H. Capdevila 5
not prevented in WY14643-treated PPARα null mice [38]. In
agreement with our ﬁnding, absence of PPARα in the host
animals abrogated the potent antitumor eﬀect of fenoﬁbrate
[48]. Finally whereas in vivo activation of PPARα prevents
vascular smooth muscle cell proliferation underlying intimal
hyperplasia, PPARα deﬁciency leads to hyperplasia [56].
Taken together, these results strongly suggest that activation
ofPPARαinthehostisakeyelementinpreventingunwanted
pathological cell growth.
Although rodents are the only species in which acti-
vation of PPARα promotes liver cancer, for a long time
it was thought that Di(2-ethylhexyl)phthalate (DEHP), a
commonly used industrial plasticizer, might cause liver
tumorigenesis presumably via activation of PPARα [55, 71].
The use of PPARα null mice has disproved this idea, as
this plasticizer is able to induce tumorigenesis in both
wild-type and PPARα-null mice [55, 71]. These results
suggest the existence of pathways for DEHP-induced hepatic
tumorigenesis that are independent of PPARα,b u tm o s t
likely dependent on DEHP-mediated oxidative stress [55].
PPARα null mice have been also instrumental to deter-
mine the role of rodent versus human PPARα in the promo-
tion of liver carcinogenesis. Morimura et al. have generated
aP P A R α-humanized mouse in which the human PPARα
is expressed in liver under control of the Tet-OFF system.
Interestingly, prolonged exposure to WY14643 in these mice
only led to a 5% incidence of liver tumors—including
hepatocellular carcinoma—compared to the 71% observed
in mice expressing the mouse PPARα [53]. More recently,
Yanget al. generated a PPARα-humanized transgenic mouse
wherethecompletehumanPPARαgenewasintroducedonto
aP P A R α-null background [54]. These PPARα-humanized
mice express the human PPARα in liver as well as other tis-
sues and respond to fenoﬁbrate treatment by lowering serum
triglycerides and by inducing the expression of enzymes
involved in fatty acid metabolism [54]. However, in contrast
to wild-type mice, treatment with fenoﬁbrate did not cause
signiﬁcant hepatomegaly, hepatocyte proliferation, and most
importantly hepatocarcinoma [54]. Thus, this study shows
that the protumorigenic let-7C/c-myc pathway is activated
onlybytherodent,butnotthehumanPPARαreceptor. Most
importantly, this work highlights the possibility that PPARα
ligands might be used as safe drugs for the treatment of
cancer in humans.
Although activation of PPARα in either endothelial or
tumor cells has been proven to be beneﬁcial in inhibiting
cancer growth, it has also been shown that loss of host-
derived PPARα c a nb ea d v a n t a g e o u sa si tp r e v e n t st u m o r
growth and development [57]. The host cells responsible
for this protection, however, are granulocytes rather than
endothelial cells. Loss of PPARα leads to an increased
inﬁltration to the side of injury of granulocytes that suppress
tumor-associated angiogenesis via excess production of the
endogenous angiogenesis inhibitor thrombospondin [57].
This study clearly indicates that both activation of PPARα
in speciﬁc host cells (i.e., endothelia cells) and concomitant
inhibition of PPARα in immuno cells (i.e., granulocytes)
might lead to the same eﬀects, namely protection from
tumor growth.
6. CONCLUSIONS
The studies summarized in this review identify PPARα as
a potential host-based target for the development of new
antiangiogenic approaches to inhibit and/or prevent tumor
growth. As an established modulator of gene transcription,
PPARα regulates the expression of genes known to be
involved in energy metabolism, cellular proliferation, and
angiogenesis and to have positive eﬀects on the control
of dyslipidemia, inﬂammation, and cardiovascular diseases.
Furthermore, several ﬁbric acid derivatives bind to and
activate human PPARα with limited or no documented
unwanted consequences and have proven to be safe and
eﬀective hypolipidemic drugs. In this context, gemﬁbrozil
safely reduced the risk of death from coronary heart disease,
nonfatal myocardial infarction, or stroke by raising HDL
cholesterol levels and lowering levels of triglycerides [72, 73].
The eﬀects of PPARα ligands in animal models of tumor
angiogenesis should help not only to stimulate further
research of their usefulness as antitumorigenic agents, but
also to facilitate their evaluation as valid tools for the
treatment and/or prevention of human cancers. In this
context, it is our hope that these studies will serve to
encourage epidemiological studies of cancer incidence in
patientsusinghypolipidemicdrugs,andhelptoidentifytheir
potential beneﬁcial eﬀects as agents for tumor prevention
and/or treatment. The urgency of new approaches for cancer
treatment are indicated by the fact that most current antitu-
morigenictherapiesareorientedtowardsageneralinhibition
of tumor cell growth and, as such, they suﬀer from lacking
target selectivity and, in most cases, causing severe side
eﬀects and overall systemic toxicity. Thus, targeting PPARα
may prove to be a potential therapeutic strategy—either
alone or in combination with conventional chemotherapy—
to inhibit and ideally prevent cancer with excellent tolerance
and limited toxicity.
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